重组马立克氏病病毒疫苗的研制现状  

The status in the research of recombinant Marek's disease virus vaccine

作　　者：李文桂[1] 陈雅棠[1] LI Wengui;CHEN Yatang(Institute of Infectious and Parasitic Diseases,the First Affiliated Hospital,Chongqing Medical University,Chongqing 400016,China)

机构地区：[1]重庆医科大学附属第一医院传染病寄生虫病研究所,重庆400016

出　　处：《中国病原生物学杂志》2023年第6期734-737,741,共5页Journal of Pathogen Biology

基　　金：国家自然科学基金项目(No.30801052,30671835,30500423,30200239)。

摘　　要：马立克氏病病毒(Marek’s disease virus,MDV)所致的马立克氏病是一种接触性及高度传染的鸡淋巴细胞增生病,临床以内脏淋巴瘤和神经损伤为特征,常接种CV1988/Rispens、SB1、301B/1和HVT-FC126等减毒或无毒疫苗株进行防治。这些疫苗株可诱导宿主产生细胞、体液和粘膜免疫应答,是一种理想的疫苗载体,可表达病毒和细菌的多种蛋白。这些疫苗包括禽流感病毒(rMDV-M2/HA/NA)、新城疫病毒(rMDV-F)、传染性法氏囊病毒(rMDV-VP2)、网状内皮增生病病毒(rMDV-LTR/env/GP90)、禽白血病病毒J亚型(rMDV-env/gag)、传染性支气管炎病毒(rMDV-S1)、传染性喉气管炎病毒(rMDV-gB/gJ)、火鸡疱疹病毒(rMDV-gB)、大肠埃希菌(rMDV-LacZ)和rMDV-IL-15等,本文综述以MDV为载体的病原体疫苗的研制现状。Marek's disease virus(MDV)is one type of etiologic agents casuing contagious,infectious lymphocytosis in avians,its clinical characteristic includes visceral lymphoma and neurotmesis,it may be controled by immunoprophylaxis with attenuated CV1988/Rispens,SB1,301B/1,and HVT-FC126 strains,those strains may induce the avians to produce cellular,humoral and mucosal immune responses,it may become ideal vaccine vector for expressing many proteins of viruses and bacteria.These vaccines include Avian influenza virus(rMDV-M2/HA/NA),Newcastle disease virus(rMDV-F),Infectious bursal disease virus(rMDV-VP2),Reticuloendotheliosis virus(rMDV-LTR/env/GP90),Avian leukosis virus subgroup J(rMDV-env/gag),Infectious bronchitis virus(rMDV-S1),Infectious laryngotracheitis virus(rMDV-gB/gJ),Herpesvirus of turkey(rMDV-gB),Escherichia coli(rMDV-LacZ),and rMDV-IL-15.The review outlines the status in the research of recombinant MDV vaccine.

关 键 词：马立克氏病病毒 疫苗 综述 

分 类 号：R852.65[医药卫生—航空、航天与航海医学] R392.11[医药卫生—临床医学]